Private company

Gan & Lee Pharmaceuticals Co., Ltd.

Gan & Lee Pharmaceuticals Co., Ltd. is a Chinese company based in Beijing, founded in 1998.1

Last updated Oct 21, 2026.

Overview

Jan 1, 1998Founded1

Timeline

  1. Jan 1, 1998Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Nov 10, 2026Phase 3 trial readout expected Phase 3 trial of GZR4 and Insulin Icodec group in Diabetes: primary completion expected Nov 10, 2026 (ClinicalTrials.gov NCT07165223).2
  2. Dec 11, 2026Phase 3 trial readout expected Phase 3 trial of GZR18 and semaglutide in Type 2 Diabetes Mellitus (T2DM): primary completion expected Dec 11, 2026 (ClinicalTrials.gov NCT06778967).3
  3. Feb 11, 2027Phase 2 trial readout expected Phase 2 trial of GZR101-80 and GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) in Type 2 Diabetes (T2DM): primary completion expected Feb 11, 2027 (ClinicalTrials.gov NCT07387003).4
  4. Jun 30, 2027Phase 3 trial readout expected Phase 3 trial of GZR18 and Semaglutide(Wegovy® ) in Obesity/Overweight in Adult: primary completion expected Jun 30, 2027 (ClinicalTrials.gov NCT07150975).5
  5. Sep 2027Phase 3 trial readout expected Phase 3 trial of GZR18 injection in Overweight or Obesity: primary completion expected Sep 2027 (ClinicalTrials.gov NCT07292441).6

Drug trials and FDA: recently

  1. Apr 7, 2026Phase 3 trial completed Phase 3 trial of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Type 2 Diabetes (T2DM): primary completion Apr 7, 2026, no results posted yet (ClinicalTrials.gov NCT07527078).7
  2. Feb 27, 2026Phase 2 trial completed Phase 2 trial of GZR18 and Tirzepatide in Obesity and Overweight: primary completion Feb 27, 2026, no results posted yet (ClinicalTrials.gov NCT06737042).8

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar